"Alameda, California-based Science is aiming to improve on current perfusion systems that continuously circulate blood through vital organs when they can no longer function on their own. The technology is used to preserve organs for transplant and as a life-support measure for patients when the heart and lungs stop working, but it's clunky and costly. Science wants to make a smaller, more portable system that could provide long-term support."
"Until now, Science's focus has been on neural interfaces and vision restoration. The company is working on a "biohybrid" interface that uses living neurons instead of wires to connect to the brain. More immediately, it's looking to commercialize its retinal implant, which successfully restored some vision in patients with advanced macular degeneration, allowing them to read letters, numbers, and words."
Science Corporation plans a new division focused on improving perfusion systems that continuously circulate blood through failing organs. The company aims to create a smaller, more portable system capable of long-term support, improving on current clunky, costly machines used for transplants and life support when heart and lungs fail. Science previously focused on neural interfaces and vision restoration, developing a "biohybrid" interface using living neurons and commercializing a retinal implant that restored some vision in advanced macular degeneration patients. Science acquired the implant from Pixium Vision in 2024 and has progressed ahead of Neuralink on vision implants. The company was founded in 2021 by Max Hodak and has raised about $290 million.
Read at WIRED
Unable to calculate read time
Collection
[
|
...
]